Market open
PDS Biotechnology/$PDSB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PDS Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ticker
$PDSB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US70465T1079
Website
PDSB Metrics
BasicAdvanced
$61M
-
-$0.94
-
-
Price and volume
Market cap
$61M
52-week high
$4.42
52-week low
$0.85
Average daily volume
241K
Financial strength
Total debt to equity
114.853
Interest coverage (TTM)
-7.98%
Management effectiveness
Valuation
Price to book
2.7
Price to tangible book (TTM)
2.7
Growth
Earnings per share change (TTM)
-31.22%
3-year earnings per share growth (CAGR)
3.85%
What the Analysts think about PDSB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for PDS Biotechnology stock.
PDSB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PDSB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PDSB News
AllArticlesVideos
EMV Capital portfolio company PDS Biotech advances cancer trial
Proactive Investors·1 day ago
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for PDS Biotechnology stock?
PDS Biotechnology (PDSB) has a market cap of $61M as of May 16, 2025.
What is the P/E ratio for PDS Biotechnology stock?
The price to earnings (P/E) ratio for PDS Biotechnology (PDSB) stock is 0 as of May 16, 2025.
Does PDS Biotechnology stock pay dividends?
No, PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next PDS Biotechnology dividend payment date?
PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders.
What is the beta indicator for PDS Biotechnology?
PDS Biotechnology (PDSB) does not currently have a Beta indicator.